Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention.

Manzoni P, Paes B, Resch B, Carbonell-Estrany X, Bont L.

Early Hum Dev. 2012 May;88 Suppl 2:S34-41. doi: 10.1016/S0378-3782(12)70012-9. Erratum in: Early Hum Dev. 2012 Oct;88(10):845. Mejias, A [removed]; Ramilo, O [removed].

PMID:
22633511
2.

Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?

Hashmi NA, Cosgrove JF, MacMahon P.

Ir Med J. 2000 Dec;93(9):284.

PMID:
11209917
3.

Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.

Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.

Pediatr Infect Dis J. 2012 Jan;31(1):e1-8. doi: 10.1097/INF.0b013e318235455b.

PMID:
21960187
4.

Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.

Fitzgerald DA.

Paediatr Respir Rev. 2009 Sep;10(3):143-7. doi: 10.1016/j.prrv.2009.06.002. Epub 2009 Jul 15. Review.

PMID:
19651385
5.

Respiratory syncytial virus disease: update on treatment and prevention.

Krilov LR.

Expert Rev Anti Infect Ther. 2011 Jan;9(1):27-32. doi: 10.1586/eri.10.140. Review.

PMID:
21171875
6.
7.

Palivizumab for the prevention of respiratory syncytial virus infection.

Rogovik AL, Carleton B, Solimano A, Goldman RD.

Can Fam Physician. 2010 Aug;56(8):769-72.

8.

Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.

Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006602. doi: 10.1002/14651858.CD006602.pub4. Review.

PMID:
23633336
9.

Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.

American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee.

Pediatrics. 2014 Aug;134(2):415-20. doi: 10.1542/peds.2014-1665. Erratum in: Pediatrics. 2014 Dec;134(6):1221.

10.

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Robinson KA, Odelola OA, Saldanha I, McKoy N.

Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007743. doi: 10.1002/14651858.CD007743.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD007743.

PMID:
20166098
12.

[Palivizumab--a monoclonal antibody for passive immunoprophylaxis of respiratory syncytial virus infections].

Scholz H.

Z Geburtshilfe Neonatol. 2000 May-Jun;204(3):120-2. German.

PMID:
10909169
14.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
15.

[Guidelines for respiratory syncytial virus prophylaxis. An update].

Carbonell-Estrany X, Quero Jiménez J.

An Esp Pediatr. 2002 Apr;56(4):334-6. Spanish.

PMID:
11927077
16.

Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.

Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC Sr.

Pediatr Crit Care Med. 2011 Sep;12(5):580-8. doi: 10.1097/PCC.0b013e3182070990. Review.

PMID:
21200358
17.

Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.

Grimaldi M, Gouyon B, Sagot P, Quantin C, Huet F, Gouyon JB; Burgundy Perinatal Network.

Pediatr Pulmonol. 2007 Mar;42(3):189-92.

PMID:
17243184
19.
20.

Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.

Prais D, Schonfeld T, Amir J; Israeli Respiratory Syncytial Virus Monitoring Group.

Pediatrics. 2003 Sep;112(3 Pt 1):548-52.

PMID:
12949282

Supplemental Content

Support Center